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In order to establish an infection, viruses need to either suppress or escape from host immune defense systems. Recent
immunological research has focused on innate immunity as the ﬁrst line of host defense, especially pattern recognition molecules
such as Toll-like receptors (TLRs), RIG-I-like receptors (RLRs), and NOD-like receptors (NLRs). Various microbial components
are recognized by their vague and common molecular shapes so-called, pathogen-associated molecular patterns (PAMPs). PAMPs
induce inﬂammatory reactions mediated by the activation of the transcription factor, NF-κB, and by interferons, which lead to
an antiviral immune response. Viruses have the capacity to suppress or escape from this pattern recognition molecule-mediated
antimicrobial response in various ways. In this paper, we review the various strategies used by viruses to modulate the pattern
recognition molecule-mediated innate immune response.
1.Introduction
The host immune system recognizes and eliminates invading
pathogenic microorganisms such as viruses, bacteria, and
fungi. The ﬁrst line of defense in mammals is the innate
immune system. Recently, the mechanisms by which the
innate immune system recognizes pathogen have been
extensively studied. Pattern recognition molecules/pathogen
recognition receptors (PRRs) are classiﬁed into three fami-
lies: Toll-like receptors (TLRs), RIG-I-like receptors (RLRs),
andnucleotidebinding-oligomerizationdomain(NOD)-like
receptors (NLRs) [1, 2]. Ten TLRs (TLR1 to 10) have been
identiﬁed in humans. The RLR family contains retinoic
acid-inducible gene I (RIG-I) and melanoma diﬀerentiation
associated gene 5 (MDA5) [3]. The NLR receptor family
contains NOD1, NOD2, NLRP3, NLRPC5, NLRP1, NAIP,
and CIITA [4]. In addition, DNA-dependent activator of
interferon regulatory factors (DAI) has been identiﬁed
as a DNA sensor [5]. Various microbial components are
recognized as their vague and common molecular shapes by
PRRs. Early responses against virus infection are initiated
on recognition of pathogen-associated molecular patterns
(PAMPs) by pattern recognition molecules, triggering two
responses. One is the production of interferons (IFNs)
resulting in an antiviral state as part of the innate immune
response, and the second is maturation of dendritic cells
(DCs) to establish acquired immunity. In order to establish
an infection within a host, viruses must escape from and/or
suppress the immune system by various strategies. An
important strategy used by viruses is modulation of PAMP-
induced immune responses.
TLR signaling proceeds via two pathways: the myeloid
diﬀerentiation factor 88 (MyD88)-mediated pathway, and
the Toll-interleukin-1 receptor (TIR)-domain-containing
adaptor inducing IFN-β (TRIF)-mediated pathway [1, 2].
The former causes activation of the transcription factor NF-
κB, which activates various genes contributing inﬂamma-
tory reactions. The latter causes induction of IFNs, whose
stimulation leads cells to antiviral state. TLR3 only activates
the TRIF-mediated pathway. TLR3 signaling activates IRF-
3, an important transcription factor for IFN-β,a n dI F N
production is induced. TLR2 only activates the MyD88-
mediated pathway. However, TLR4 activates both pathways,
soTLR4agonistsactivateNF-κBandinduceIFNproduction.
Cytosolic PRRs, such as RIG-I, MDA5, and DAI, commonly
activate IRF-3. The expression of PRRs diﬀers depending on2 Mediators of Inﬂammation
the cell type. Importantly, it is diﬀerent between cells derived
from myeloid stem cells (myeloid dendritic cells (mDCs),
monocytes,macrophages,Langerhanscells,andneutrophils)
and cells derived from lymphatic stem cells (plasmacytoid
dendritic cells (pDCs), T cells, and B cells). For example,
TLR7 and TLR9 are rarely expressed on mDCs, whereas
TLR3 and TLR8 are rarely expressed on pDCs. TLR4, on the
other hand, is expressed at very low levels on both pDCs and
mDCs.
2.VirusesandInnateImmunity
Initially, viruses invade the host epithelial tissues found
in the oral cavity, respiratory tract, intestinal tract, and
the urogenital apparatus (Figure 1). Lamina propria DCs,
Langerhans cells, and stromal cells are resident in these
tissues. In the connective tissues, ﬁbroblasts resident, and
capillary vessel and lymphatic vessel are expanded. Mono-
cytes, macrophages, T cells, B cells, pDC, and mDC circulate
within the blood vessels and lymphatic vessels, and patrol
the interstitial spaces. All these cells are potential targets for
virus infection. Virus-infected epithelial cells and ﬁbroblasts
produce IFNs, mainly IFN-β and IFN-λ, which provide
surrounding uninfected cells with antiviral state. Further-
more, chemokines and cytokines, such as interleukin-1β (IL-
1β), IL-6, IL-8, granulocyte-macrophage colony-stimulating
factor (GM-CSF), and tumor necrosis factor-α (TNF-α)a r e
also produced. These molecules promote chemotaxis of the
resident DCs (lamina propria DCs and Langerhans cells)
toward virus-infected and dead cells. Neutrophils, mono-
cytes, macrophages, plasma cells, mDCs, and pDCs also
migratefromthebloodvesselstothesiteofinfection.IFN-γ-
inducible protein 10 (IP-10), monocyte chemotactic protein
1 (MCP-1), macrophage inﬂammatory protein-2 (MIP-2),
MIP-3α,a n dM I P - 3 β largely contribute to the transmigra-
tion of blood DCs. However, these blood-borne immune
cellscanalsobeinfectedbyviruses,whichcanthenmodulate
the production of various cytokines and chemokines.
To establish an infection, viruses need to suppress a
number of host immune responses, the antiviral activity
induced by IFNs, the chemotaxis of immune cells induced
by chemokines/cytokines, the maturation and activation of
DCs, activation of NK and NKT cells, transmigration of
mature DCs to the lymph nodes, and the diﬀerentiation and
activation of T cells and B cells in the lymph nodes, for
example. When viruses infect immune cells, such as DCs,
the infected cells frequently show suppression of maturation
and diﬀerentiation, suppression of cytokine receptor and
costimulatory molecule expression, secretion of molecules
that mimic cytokines and cytokine receptors, and so on.
Furthermore, infected cells often alter their cytokine proﬁles.
These strategies are used by the virus to inhibit the acquired
immune response. In addition, it has been suggested that
virus infection induces regulatory T cells.
3.RNA Virus
3.1. Human T Lymphotropic Virus Type 1 (HTLV-1). HTLV-
1, which is a retrovirus, infects CD4+ Tl y m p h o c y t e s ,C D 8 +
T lymphocytes, DCs, B cells, macrophages, and astrocytes,
and preferentially replicates in CD4+ Tl y m p h o c y t e s .H T L V -
1 causes latent infection as a provirus, whose genome is
integrated into the host DNA, and does not replicate in
cells in G0 phase. When the infected T lymphocytes are
stimulated with antigen presentation from DCs, they prolif-
erate triggering HTLV-1 replication. During the replication
stage, a viral protein, Tax, activates NF-κB and promotes the
growth of infected cells via upregulation of IL-2 and IL-2
receptors [6,7].NF-κBalsoactivatesthelongterminalrepeat
(LTR) of HTLV-1 genome, which further enhances viral
replication [8]. The replicated virus induces a host immune
response, and cells infected with virus are eliminated by the
induction of cytotoxic T cells speciﬁc for HTLV-1 Tax. In
patientswithHTLV-1-associatedmyelopathy/tropicalspastic
paraparesis (HAM/TSP), the high proviral load induces a
strong HTLV-1-speciﬁc immune response [9]. This leads
to the rapid elimination of infected cells through the
induction of proinﬂammatory cytokines and cytotoxic T
lymphocytes. So, in order to escape from acquired immune
responses, HTLV-1 needs minimum replication and latent
infection.
Some virus proteins are known as negative regulators of
replication. The HTLV-1 basic leucine-zipper factor (HBZ)
protein suppresses Tax-mediated transcription activation of
the viral LTR [10]. The p30 protein suppresses transcription
of mRNAs encoding Tax and Rev [11]. p30 also contributes
to the expression of TLR2, TLR4, and TLR9, and activation
of IRF4. In monocytes, the TLR2 gene promoter is regulated
by the transcription factors Sp1, Sp3, and PU.1 [12], and
the TLR4 gene by ISRE and PU.1 [13]. p30 downregulates
the expression of both TLR2 and TLR4, because it binds to
PU.1andpreventsitfrombindingtoDNA[14].Thisleadsto
the suppression of DC maturation, and of their subsequent
migration to the lymph nodes. Furthermore, p30 suppresses
the enzymatic activity of glycogen synthetase kinase 3β
(GSK3β) through promotion of the phosphorylation of
nine serine residues. This leads to the induction of IL-10,
which suppresses the function of macrophages, and also
the maturation and activation of DCs. In fact, serum IL-
10 levels are elevated in patients with adult T lymphocyte
leukemia. These immunosuppressive properties of IL-10
indirectly contribute to the inhibition of virus replication
and to the suppression of virus-induced immune responses.
Activation of infected T lymphocytes by DCs in the lymph
nodes and cell-to-cell transmission of virus are considered
to be important for virus proliferation in human. The viral
p12 protein suppresses cell surface expression of both MHC
class I and the IL-2 receptor, and also suppresses linker for
activation of T cells (LAT), which is an adaptor protein
requiredforTcellactivation[15].Thisresultsinsuppression
of T cells and dystunction of the stimulation/activation by
DCs via the T cell receptor. HTLV-1 causes proliferation
of infected cells rather than virus and suppression of host
immune responses, which helps it to maintain a latent
infection in order to survive.
3.2. Human Immunodeﬁciency Virus (HIV). HIV is another
retrovirus that uses similar escape strategies to HTLV-1. HIVMediators of Inﬂammation 3
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Figure 1: Process of innate immunity to acquired immunity.
can infect CD4+ T lymphocytes, monocytes, macrophages,
and DCs, and preferentially replicates in activated T lym-
phocytes and activated macrophages. It replicates generally
much more slowly in DCs regardless of maturation stage.
HIV establishes a latent infection in resting T lymphocyte,
and T lymphocyte activation by DCs or stimulation with IL-
2 is thought to trigger active replication of the virus. Resting
T lymphocytes show resistance to infection and proliferation
of HIV. Apolipoprotein B mRNA editing enzyme catalytic
polypeptide-like 3G (APOBEC3G) is important for this
resistance [16, 17]. The antiviral mechanisms of APBEC3G
are considered to act via inhibition of viral reverse tran-
scriptase (RT). It also produces a transition (G to A) in the
DNA strand transcribed by RT due to its cytidine deaminase
activity. However, a mutant lacking cytidine deaminase
retains antiviral activity. Low molecular weight complexes
of APOBEC3G (LMM: 70–100kDa) have antiviral activity,
but high molecular weight complexes (HMM: 700kDa) do
not. The Vif protein of HIV converts LMM to HMM,
and promotes proteasome-dependent degradation of the
complex, so HIV can counteract its antiviral activity [18]. T
cellactivationleadstoconversionofLMMtoHMM(proviral
environment). On the other hand, IFNs induce LMM type
(antiviral environment) [19, 20].
During the early stage of HIV infection, clinical symp-
tomssho wsingsofimmunesystemactivationsuchasﬂu-lik e
symptoms,ratherthanimmunosuppression.Immunological
activation is caused by RNA40, an oligonucleotide derived
from HIV, which activates pDCs, mDCs, T lymphocytes, and
monocytes via TLR7 and TLR8 [21]. The virus proteins, Tat
and Vpr, induce proinﬂammatory cytokines via activation
of NF-κB[ 22, 23], which then enhances the transcription
of the virus genome via the LTR. IL-8 also contributes to
the propagation of the virus via the accumulation of T
lymphocytes.
Enhanced proliferation of HIV causesimmune responses
that attempt to eliminate the virus. So, HIV maintains a
latent infection in order to survive within the host. The
Vpu protein suppresses NF-κB activation by inhibition of
proteasome-dependent degradation of IκB[ 24]. The Nef
protein suppresses phosphorylation of ERK through induc-
tion of a phosphatase MKP-1 [25]. This causes suppression
of TNF-α production by macrophages via TLR4 signaling.
BecauseTNF-αisnecessaryformaturationandtranslocation
of DCs (including Langerhans cells) to the lymph nodes,
downregulation of TNF-α leads to suppression of acquired
immune responses, and so prevents inhibition of virus
proliferation by activated T lymphoctes. Furthermore, Nef4 Mediators of Inﬂammation
Table 1: Molecular mechanisms involved in modulation of host innate immune systems by viruses.
Virus/Virus protein Host pathway Function Eﬀect
RNA virus
Human immunodeﬁciency virus (HIV)
Nef TCR-CD30 Inhibit NF-κB and AP-1
activation Inhibit T cell activation
TLR4
Inhibit ERK activation
(Dephosphorylation of
ERK by induced MKP-1)
Suppress TNF-α production
Vpu TLRs Inhibit NF-κB activation
(Stabilize IκB) Suppress cytokine production
Tat Activate NF-κB
(PKR-dependent)
Vpr Activate NF-κB Enhance IL-6, IL-8, and IL-10
production
RNA40 TLR7/8 Activate IRF-7 mediated by
MyD88 Activate pDCs
Human T-lymphotropic leukemia virus 1 (HTLV-1)
p30 TLR4 Suppress TLR4 expression
(Suppress PU.1 fuction) Suppress cytokine production
Inhibit GSK3-β Enhance IL-10 production
p12 TCR Suppress phosphorylation
of PLC-γ1 and Vav
Suppress T cell activation by
DCs
Tax Activate IKK (Bind to
IKKγ)
Induce IL-2, IL-2R, GM-CSF,
and IL-15
Hepatitis C virus (HCV)
NS3/4A TLR3/4 Degrade TRIF Suppress IFN-α/β production
Suppress CD4+ Tc e l l
activation by dysfunction of
mDCs
NS5A TLRs Inhibit NF-κB activation
(Bind to MyD88) Suppress cytokine production
Inhibit JNK activation
(Bind to TRAF2)
Suppress TNF pathway
activation
core, NS3 TLR2 Activate MAP kinase
pathway, NF-κB, and AP-1
Dysfunction of pDCs by
enhanced production of IL-10
and TNF- α
Measles virus
N( ? )
Suppress IL-12 production
mediated by TLR4 in DCs
(Suppress Th1 diﬀerentiation)
P TLR2/4
Suppress NF-κB and AP-1
activation (Upregulate host
NF-κB negative regulator
A20)
Inhibit proinﬂammatory
cytokine and chemokine
production
HA TLR2 Activate NF-κB Induce cytokine production
Inﬂuenza virus A
NS1 TLR3/7/9 Suppress of IRF3/7
activation
Inhibit IFN production in
pDC
TLR4 Suppress of NF-κBa n d
AP-1 activation
Suppress DC and T cell
activation
RIG-I Suppress of IRF3/7
activation
Inhibit IFN production in
mDCMediators of Inﬂammation 5
Table 1: Continued.
Virus/Virus protein Host pathway Function Eﬀect
SARS-coronavirus (SARS-CoV)
N
Activate AP-1
Bind to NF-κB and C/EBP
binding motifs of IL-6
promoter
Induce IL-6 and COX-2
promoter
Human respiratory syncytial virus (RSV)
G TLR2/4/9 Suppress NF-κB activation Suppress cytokine production
FT L R 4 A c t i v a t e N F - κB Induce IL-1, IL-6, IL-8, and
RANTES
M2-1 Activate NF-κB
? TLR7/9 Suppress IFN production in
pDC
NS1, NS2 TLR3/4, RIG-I Suppress IRF3 activation Suppress IFN production in
mDC
Rotavirus
VP4
Activate NF-κB
Suppress JNK
(Bind to TRAF2)
DNA virus
Vaccinia virus
A46R TLRs
Suppress NF-κB activation
(Bind to MyD88, TRAM,
and TRIF)
Suppress cytokine production
A52R TLRs Suppress NF-κB activation
(Bind to IRAK2) Suppress cytokine production
Activate p38 MAPK and
JNK (Bind to TRAF6) Induce IL-10 production
N1L TLRs Suppress NF-κB activation
(Bind to IKKγ) Suppress cytokine production
Suppress IRF3 activation
(Bind to TBK1) Suppress IFN production
Adenovirus
RID TLR4 Suppress NF-κB and AP-1
activation
Suppress MCP-1 and IL-8
production
TNF pathway Suppress TNFR1
expression
Suppress MCP-1 and IL-8
production
capsid Activate NF-κB, ERK, and
MAPK Induce RANTES and IL-10
Herpes simplex virus (HSV)
virion TLR2 Induce cytokine production
viral DNA TLR9 Induce IFN production
Varicella-zoster virus
vrion TLR2 Induce cytokine production
Human cytomegalovirus (HCMV)
late proteins IL-1 system
Suppress NF-κB activation
(Inhibit site located
upstream of MAP3K)
TNF system Suppress TNFR1
expression
gB/gH TLR2/1 Activate NF-κB Produce proinﬂammatory
cytokines6 Mediators of Inﬂammation
Table 1: Continued.
Virus/Virus protein Host pathway Function Eﬀect
Epstein-Barr virus (EBV)
late protein Suppress NF-κB activation Inhibit COX-2 activation
gp350/gp220 TLR2/CD21 Activate NF-κB Induce MCP-1 production
LMP-1 Activate p38 MAPK
(TRAF6-dependent)
Suppress DC function by
induced IL-10
Human herpesvirus 8 (HHV8)
vFLIP Activate IKK
(Bind to IKKγ)
RTA Degrade IRF7 by
proteasome system Suppress IFN-α/β production
Hepatitis B virus
e antigen IL-1 pathway Activate NF-κB Induce cytokine
(Bind to mIL-1RAcP) production
inhibits T cell receptor induced lymphocyte activation [26].
These strategies contribute to the suppression of HIV prolif-
eration in the lymph nodes, and also inhibit the propagation
of infection. Other immunosuppressive mechanisms used
by HIV have also been reported. Cosuppressive molecules,
such as B7-H1 on DCs and PD1 on T lymphocytes, are
upregulated in patients with HIV, and induce apoptosis
through their interaction with DCs and T lymphocytes. In
addition, HIV is thought to induce regulatory T cells [27].
3.3. Hepatitis C Virus (HCV). HCV does not only infect
hepatocytes.ItcanalsoinfectDCs,macrophages,monocytes,
and T lymphocytes. However, the virus does not replicate
eﬃciently in these cell types. Although, virus particles and
virus proteins are found in the blood of HCV patients.
HCVcausesnocytopathiceﬀects.Immuneresponsesagainst
HCV may be weak, but infected cells are attacked and
eliminated. In order to survive in the host, HCV maintains a
chronicinfectionbysuppressingthehostimmuneresponses.
Both HCV core and NS3 proteins activate NF-κBa n d
AP-1 via stimulation of TLR2, which requires TLR1 and
TLR6 as costimulators, in monocytes and Kupﬀer cells
[28]. This activation leads to the production of IL-10 and
TNF-α, both found in HCV patients at a high titer. IL-10
suppresses the maturation of pDCs and the activation of
T lymphocytes, and induces apoptosis in pDCs. The NS3-
NS4A protein complex, which is a serine protease, degrades
TRIF and IPS-1/Cardif/MAVS/VISA, which are essential for
cellular signaling via TLR3, TLR4, and RIG-I [29]. This
shutting oﬀ of TRIF- and IPS-1-dependent signaling results
in the suppression of IFN-α and IFN-β production, and in
dysfunction of mDCs.
The NS5A protein suppresses activation of IRAK-1
through its interaction with MyD88. This leads to the
shutting oﬀ of TLR7 and TLR8 signaling, and to the
suppression of maturation and diﬀerentiation of pDCs [30].
On the other hand, NF5A suppresses TRAF2 dependent NF-
κB activation via interaction with NF5A and TRAF2, but
suppress neither MEK1 activation nor IKKβ-dependent NF-
κBa c t i v a t i o n[ 31]. TNF-α-dependent activation of JNK is
enhanced. Infected DCs are thought to aﬀect the production
of TNF-α,T N F - α signal transduction, and chemotaxsis
and maturation. Dysfunction of DCs, suppression of T
lymphocyte activation, and a decrease in DC number due
to apoptosis allow HCV to establish a chronic infection
[32]. It has also been reported that HCV-speciﬁc cytotoxic
T lymphocytes share upregulated expression of the coin-
hibitorymoleculePD-1,andthatsignalingfromPD-1L(PD-
1 ligand) on DCs results in suppression of HCV-speciﬁc
cytotoxic T lymphocytes [33].
3.4. Measles Virus. Measles virus infection causes strong
immunosuppression. Measles virus wild strains (clinical
isolates) recognize CD150/SLAM (signaling lymphocyte
activation molecule) as a receptor. However, laboratory
(vaccine) strains only recognize CD46. SLAM is strongly
expresseed on memory T cells and B cells, but is also
expressed on monocytes, T cells, B cells, and matured DCs.
SLAM is not expressed on immature DCs, epithelial cells,
and endothelial cells. On the other hand, CD46 is expressed
on variety of cell types. Infection of SLAM-negative mucosal
epithelial cells with measles virus wild strains is thought to
be mediated by an as yet unknown “third” receptor [34, 35].
The HA protein of wild virus strain, but not the laboratory
strain,inducescytokinessuchasIL-1α,IL -1β,IL -6,IL -8,and
IL-12 via the TLR2 signaling pathway [36]. These cytokines
activateandrecruitimmunecellstothesiteofinﬂammation,
where the activated immune cells are infected with measles
virus via SLAM. The infection and cytokine production are
thus propagated.
Interaction of the HA protein with SLAM suppresses
TLR4-mediated IL-12 production, but not IL-6 and TNF-α
p r o d u c t i o n .H o w e v e r ,I L - 1 2p r o d u c t i o nm e d i a t e db yo t h e r
TLR signaling pathways (i.e., not via TLR4) is unaﬀected
by the HA protein [37]. These observations suggest that
SLAM is a coupling factor for TLR4, and that the HA
protein inhibits this function. The HA protein also inter-
acts with a C-type lectin, dendritic cell-speciﬁc ICAM-3-
grabbing nonintegrin (DC-SIGN) on DCs, and activates the
serine/threonine protein kinase Raf-1 via the Ras signalingMediators of Inﬂammation 7
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pathway.DC-SIGN-mediatedRaf-1activationinducesphos-
phorylation of NF-κBp65 on Ser-276, and its subsequent
acetylation. This leads to the enhanced transcription of
IL-10 [38]. During infection stage that virus proteins are
synthesized de novo, the host cells, such as monocytes
and DCs, infected with measles virus show suppressed IL-
12 production and TLR signaling, via TLR2, TLR4, TLR7,
and TLR9. pDCs infected with the measles virus showed
suppressed IFN production and dysfunction of maturation
[39, 40].
Both monocytic cell lines U937 and THP-1 and human
peripheral blood mononuclear cells infected with measles
virus show markedly suppressed TLR2- and TLR4-mediated
proinﬂammatory cytokine induction via NF-κB and AP-1
[41]. However, epithelial cells infected with measles virus
show constitutive activation of NF-κB and proinﬂammatory
cytokine production, and these are further enhanced by
treatment with TLR agonists such as lipopolysaccharide
(LPS). Monocytic cell lines infected with the mumps virus,
which also belongs to the Orthomyxoviridae family, show
constitutive activation of NF-κB and constitutively high
levelsofIL-8production.Inmonocyticcellsinfectedwiththe
measles virus, LPS-induced ubiquitination (probably K63-
linked type) of TNF receptor-associated factor 6 (TRAF6)
is suppressed and does not form active complexes of TAK1,
TAB2, and TRAF6. An ubiquitin-modifying enzyme A20,8 Mediators of Inﬂammation
which is a host NF-κB negative regulator, is upregulated in
measles virus-infected monocytic cells, but not in infected
epithelial cells. The promoter region of the A20 gene shares
two NF-κB binding sites and a negative regulatory motif,
ELIE, which is located upstream of, and adjacent to the
two NF-κB binding motifs. Measles virus P protein (phos-
phoprotein) interacts with the ELIE motif, and activates
transcription of A20. P protein is thought to release the
suppressed A20 transcription machinery independently of
activated NF-κB[ 42]. The reason for cell-type speciﬁc A20
expression is unclear. However, the measles virus V protein,
which is formed by RNA editing of the P genome and has
an N terminal amino acid sequence identical to that of P
protein, does activate NF-κB. The balance of the expression
levels and time courses of the P and V proteins may also
contribute to the cell-type speciﬁc suppression of TLR
signaling pathways.
3.5. Inﬂuenza Virus. The NS1 protein of type A inﬂuenza
viruses suppresses innate immune system signaling activated
by the PAMPs, via TLR3, TLR4, RIG-I, and MDA5 system.
The suppression should contribute to eﬃcient replication of
infected virus in respiratory epithelial. The mechanism of
suppression is mainly via inhibition of IRF-3 phosphoryla-
tion [43], leading to suppressed induction of IFN-α/β,a n d
IFN-λ1, 2, and 3. In addition, inhibition of NF-κB and AP-1
activationininﬂuenzavirusinfectedcellsleadstosuppressed
proinﬂammatory cytokine production, for example, IL-8
and TNF-α. Inﬂuenza virus NS1 protein is known to be
a multifunctional protein able to inhibit the type I IFN
induction, the IFN-induced antiviral activity, the binding
and sequestration of dsRNA, the interference with the host
mRNAprocessing,thefacilitationofpreferentialviralmRNA
translation, and the inhibition of DC activation [44, 45].
3.6. Human Respiratory Syncytial Virus (RSV). RSV F pro-
tein causes TLR4-mediated NF-κB activation during the
early infection stages of infection that is dependent upon
virus replication. IL-1β, IL-6, and IL-8 are induced via NF-
κB activated by the stimulation of TLR4. During the late
stages, the viral G protein is produced, and secreted, which
then suppresses TLR4-mediated signal transduction [46].
The cysteine-rich (GCRR) region of the G protein is also
important for NF-κB suppression. Following the interaction
of virus proteins with host cell surface proteins, the viral M2-
1 protein inhibits the translocation of RelA, a component
of NF-κB, to the cell nucleus [47]. Expression of the viral
nonstructural proteins, NS1 and NS2 inhibit activation of
IRF3 induced by TLR3, TLR4, and RIG-I signaling, and
also suppress IFN production [48]. However, NS1 and NS2
proteins have little eﬀect on NF-κB or AP-1 activation, so the
production of proinﬂammatory cytokines may be eﬀectively
induced in the RSV-infected cells.
4.DNA Virus
4.1. Vaccinia Virus. Orthopox viruses, including the vaccinia
virus, produce proteins that mimic cytokine receptors, such
as those for IFN-α,I F N - β,I F N - γ,I L - 1 β, IL-18, and TNF-
α, and disturb the cytokine signal transduction system.
Other viral proteins also disturb the intracellular signal
transduction systems. The viral A46R protein has a TIR
domain, and interacts with MyD88 and TRIF, suppressing
bothIL-1andTLRsignaltransduction,butnotTNF-αsignal
transduction [49]. The viral A52R protein binds to IRAK2,
suppresses TRAF6-dependent IKK and NF-κB activation,
andtheninhibitsproductionofIL-8andRANTES.However,
A52R also binds to TRAF6 and promotes polyubiquitination
of TRAF6, TAK1 activation, MAPKK6 phosphorylation, and
activation of the JNK-p38 MAP kinase pathway. The later
leads to the induction of IL-10 production [50]. The viral
N1L protein interacts with the IKK complex (IKKα-IKKβ-
IKKγ), TBK1, and IKKε, and then suppresses the activation
of NF-κBa n dI R F - 3[ 51]. Vaccinia virus not only suppresses
proinﬂammatory cytokines, but also induces production of
an immunosuppressive cytokine IL-10, which shifts the Th1
response and suppresses cellular immunity. Human mono-
cytes infected with vaccinia virus produce IL-10, and this IL-
10 is then further upregulated by stimulation with LPS [52].
4.2. Adenovirus. During the early stages of infection, aden-
ovirus particles induce the MyD88-dependent production of
RANTES, IP-10, and MIP-1 [53]. The cytokines produced
enhance both sensitivity to LPS and the production of
TNF-α.T N F - α suppresses the formation and maturation
of virus particles, and induces apoptosis of infected cells.
TNF-α also promotes the chemotaxis and maturation of
dendritic cells. The induction of TNF-α is considered to be
a host defense response. On the other hand, the adenovirus
E1A and E3 proteins inhibit TNF-α-induced apoptosis.
The receptor internalization and degradation (RID) com-
plex, which consists two E3 products, E3(10.4k)/RIDα and
E3(14.5k)/RIDβ, suppresses cell surface expression of Fas,
TNF-related apoptosis-inducing ligand (TRAIL) receptor 1,
TRAIL receptor 2, and TNF receptor 1 [54, 55]. This results
in the shutting down of the TNF-α-mediated signaling
pathways in the infected cells. RID also suppresses the TLR4
signaling pathway. LPS-induced MCP-1 and IL-8 production
are suppressed through the inhibition of NF-κB and AP-1
activation [56]. RID does not alter the expression levels of
TLR4, and so is thought to aﬀect other components of the
TLR signal transduction pathway.
4.3. Human Cytomegalovirus (HCMV). HCMV modulates
NF-κB activity during the various stages of infection.
During the early stages, the membrane glycoproteins gB
and gH interact with TLR2 and activate NF-κB[ 57]. NF-
κB then contributes to the induction of proinﬂammatory
cytokines, to the expression of virus immediate early
genes, and to the replication of the viral genome. The
viral US28 protein, which is a HCMV-encoded chemokine
receptor, constitutively activates both NF-κBa n dp h o s -
pholipase C signaling pathways [58]. The activated NF-
κB mediates the upregulation of the host serine/threonine
protein kinase, receptor-interacting protein-like interacting
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RICK, which has a caspase-recruitment (CARD) domain,
functions downstream of the pattern recognition receptors
(which include the TLR, RLR, and NLR family members)
and mediates NF-κB and MAP kinase activation. RICK
suppresses the replication of HCMV in cooperation with
active NF-κBa n dI F N - β [59]. Not to be outdone, the late
gene products of HCMV also suppress NF-κBa c t i v a t i o n[ 60,
61]. TNF-α signaling is suppressed through downregulation
of TNF receptor 1. IL-6, IL-8, and MCP are not induced
in HCMV-infected cells and chemotaxsis, activation, and
maturation are all suppressed.
4.4. Epstein-Baar Virus (EBV). EBV mainly infects B cells,
although it can also infect T cells, NK cells, and epithelial
cells. Both the attachment of EBV to receptor CD21 and the
interactionofthevirusglycoproteingp350-gp250withTLR2
activate NF-κB[ 62]. The virus gB and gH proteins are also
candidates for TLR2 ligands. Immortalization of B cells by
EBV infection is due to the activation of NF-κB by the latent
membrane protein 1 (LMP1), and antigen stimulation-like
signaling of the B cell receptor by LMP-2. TLR2 signaling
suppresses the transcription of the TLR9 gene via activation
of NF-κB containing p65 protein. So downregulation of
TLR9 and upregulation of TLR7 and MyD88 are observed
in EBV-infected cells [63]. Cell proliferation is thought
to be driven by TLR7 signaling activated by virus RNA,
because the TLR7 antagonist IRS661 suppresses cell division.
Small RNA encoded by the EBV genome (EBV-EBERs)
activates TLR7 signaling, and induces IL-10 production.
TLR7 signaling also upregulates and activates IRF-5, and
inducesproinﬂammatorycytokines.However,activatedIRF-
5 is negatively regulated by EBV-induced IRF-4 and a splice
variant of IRF-5 (V12IRF-5) [63]. This suggests that the
TLR7 signaling system play a role in the cell division of EBV-
infected cells, and in the establishment of persistent infec-
tion. Lytic infection and production of virus particles are
observedduringthelatestageofEBVinfection.Lateproteins
suppress NF-κB activation. This leads to the downregulation
of proinﬂammatory cytokines, the upregulation of TLR9,
and the suppression of TLR7 function through interaction
of TLR7 and TLR9. So the TLR9 system should be important
during late stage of EBV infection.
5. Concluding Remarks
Virusesareinaconstantbattlewiththehostimmunesystem.
Viruses modulate both the innate and acquired immune
systems using a number of clever strategies. The goal appears
to be to survive within the host for a long time, rather
than eﬃcient replication. Excessive replication would lead to
detection and elimination by the host innate and acquired
immune systems, thus bringing about the death of the
virus. The virus needs to strike a balance between activation
and suppression of host immune response. It is likely that
each virus has developed various strategies to modulate the
host immune response individually, and viruses that have
succeeded in creating a good balance between host and
parasite have survived.
Modiﬁcation of TLR signaling is a promising strategy
for treatment of cancer, allergy, and infectious diseases [64,
65]. Especially, the immunomodulators should not generate
resistant virus to drugs compared to antiviral drugs targeting
viral proteins. As an existing example of virus infection,
imiquimod, which is a TLR7 agonist, have been applied
to an infectious disease caused by human papilloma virus,
namely, condylomata acuminata [66]. TLR4 antagonists are
trying to be applied to treatment of sepsis. Several issues
must be considered for the clinical application of TLR
signaling. Among the greatest is assessment of what are
keys of host defense or virus survival in view of a series of
viral infection process. For example, human herpes simplex
v i r u s1( H S V - 1 )r e q u i r e sa c t i v a t e dN F - κBf o ri t se ﬃcient
replication [67]. On the other hand, NF-κBh a sak e yr o l e
in inﬂammatory reactions via transcription activation of
proinﬂammatory cytokines, cell adhesion molecules, and
MHC. Thus, activation of NF-κB is a double-edged sword
for HSV-1. In the host side, TLR signaling varies according
to organs and tissues. For example, intestinal epithelial
cells express low levels of TLRs and high levels of negative
regulators of TLR signaling, such as Tollip [68, 69]. Also,
in intestinal immunity, NF-κB activation in a subset TLR
signaling in DCs and macrophages is suppressed by a
negative regulation IκBNS [70]. The dysregulation of TLR
signaling in the lumen of intestinal epithelial causes limit
chronic inﬂammatory activation induced by commensal
bacteria. Various TLR polymorphisms have been found, and
some of them are shown to contribute to dysregulation of
TLR signaling. The dysregulation has been suggested to be
linked with a number of disease sensitivity and condition
depending on individual diﬀerences [71, 72].
In conclusion, the molecular mechanisms involved in
modulation of host immune systems, including TLR signal-
ing, give us important hints on how to overcome infectious
diseases caused by viruses.
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